scholarly journals Epidemiology and therapeutic management of highly active relapsing-remitting multiple sclerosis adults in the French national health insurance database

2021 ◽  
Author(s):  
Arnaud Kwiatkowski ◽  
Marianne Payet ◽  
Emmanuelle Préaud ◽  
Ludovic Lamarsalle ◽  
Fanny Raguideau ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Management ◽  
Specific Information ◽  
Discharge Data ◽  
Highly Active ◽  
Incidence And Mortality ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Insurance Database

Abstract Background: In France, no specific information on the Highly Active Relapsing-Remitting Multiple Sclerosis (HA-RRMS) population is available.Objective: To describe the epidemiology and therapeutic management of HA-RRMS patients in France.Methods: In this cohort study, HA-RRMS patients were identified in the health data system with a new algorithm using outpatient healthcare consumption and hospital discharge data. Results: Over 2010–2015, 9,596 incident HA-RRMS patients were identified (sex ratio: 2.8; mean age 39.9 years old) and followed-up for 4.0 years, on average. In 2015, the incidence and mortality rates in patients aged 20 and above were 3.6 and 389 per 100,000, respectively (lower mortality than in the MS population but twice as high as in the French population). During the study, 39.7% of patients took a disease-modifying drug (DMD) and 83.5% a high efficacy DMD (HE-DMD, fingolimod or natalizumab, with a mean treatment duration of 3.5 years). When patients treated by an HE-DMD required to switch to another treatment, it was more often to the other HE-DMD (more often from natalizumab to fingolimod) than to a DMD. Conclusions: According to this first real-world study, HA-RRMS patients could represent 8% of MS patients. The results validated the algorithm to identify HA-RRMS patients.

Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab

2017 ◽  
Vol 7 (3) ◽  
pp. 175-181 ◽  
Author(s):  
José Eustasio Meca-Lallana ◽  
Ester Carreón-Guarnizo ◽  
Rocío Hernández-Clares ◽  
Estefanía García-Molina ◽  
José Díaz-Pérez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
First Line ◽  
Highly Active ◽  
Relapsing Remitting ◽  
Radiological Control ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis

2015 ◽  
Vol 73 (3-4) ◽  
pp. 220-229 ◽  
Author(s):  
Álvaro Cobo-Calvo ◽  
Laura Bau ◽  
Elisabet Matas ◽  
Lucía Romero-Pinel ◽  
M. Alba Mañé Martínez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Highly Active ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

2021 ◽  
Vol 47 (1) ◽  
Author(s):  
Elisabetta Godano ◽  
Fabio Barra ◽  
Alessandra Allodi ◽  
Antonella Ferraiolo ◽  
Alice Laroni ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Unplanned Pregnancy ◽  
Critical Role ◽  
Highly Active ◽  
Relapsing Remitting ◽  
The Status ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Maternal Disease

Abstract Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women with highly active disease who plan a pregnancy or have an unplanned pregnancy, after accurate counseling about eventual maternal disease relapse due to therapy suspension. Case presentation This brief case report describes a case of documented anemia that we observed in a newborn whose mother with relapsing-remitting multiple sclerosis was treated with an extended dosing protocol of natalizumab throughout pregnancy. The newborn received the infusion of erythropoietin every seven days from the fortieth day of life; subsequently, the status of anemia underwent clinical resolution. Conclusions This case report confirmed that natalizumab can cause disorders of hematopoiesis, including anemia, thrombocytopenia, or pancytopenia, in newborns of patients treated during pregnancy. A multidisciplinary team, including experienced pediatricians and pediatric hematologists, has a critical role in managing newborns delivered by women, being treated with natalizumab for treating relapsing-remitting multiple sclerosis during pregnancy.

Sign in / Sign up

Export Citation Format

Share Document